Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Gastrointestinal Stromal Tumors 6Leukemia, Myeloid, Chronic-Phase 4Leukemia 4Neoplasms 2Neoplasm Metastasis 2Melanoma 2Sarcoma 1Relapsed Pediatric Solid Tumor 1Mesothelioma 1Meningioma 1Leukemia, Myeloid 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1GIST 1Drug-Related Side Effects and Adverse Reactions 1Chordoma 1Central Nervous System Neoplasms 1Carcinoma, Adenoid Cystic 1Brain Neoplasms 1

Interventions

pazopanib 2Ifosfamide 2Etoposide 2Carboplatin 2vandetanib 1ruxolitinib 1fludarabine 1Vemurafenib 1Trastuzumab 1Sorafenib 1Imatinib Mesylate 1Everolimus 1Erlotinib Hydrochloride 1Dasatinib 1Cytarabine 1Crizotinib 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Relapsed Pediatric Solid Tumor × Imatinib Mesylate × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡